Clin infect dis

Literaturrecherche Produkt (Wirkstoff)
Intervall: 1.1.2006 – 15.1.2006

Das Bewertungssystem:

! . Besprechungsrelevant! Vollpublikation unbedingt empfehlenswert
• Der Artikel betrifft unmittelbar das Produkt • Der Artikel eignet sich als Infoletter für den Außendienst und / oder für Ärzte • Auflistung von Abstract, Zusammenfassung, Kommentar / Begründung der Empfehlung 9 . Abstract genügt
• Der Artikel hat Bezug zum Produkt oder zur Indikation oder zu einem Konkurrenzprodukt, Detailinformationen der Vollpublikation sind jedoch nicht nötig • Das Abstract ist als Hintergrundinformation zu gebrauchen • Auflistung von Abstract, Zusammenfassung, Kommentar X . nicht relevant
• Der Artikel betrifft das Produkt, bleibt aber vorerst ohne Konsequenzen, z.B. präklinische ! Zusammenfassung
Offene, prospektive Kohorten-Studie mit vereinzelten Fallstudien zur Untersuchung von
Kombinationen aus Statinen, Aspirin, ß-Blockern und Inhibitoren des Angiotensin-
konvertierenden Enzyms in der sekundären Verhinderung aller Todesursachen bei
Patienten mit ischämischem Herzleiden.
Empfehlung
===Die Empfehlung wird produktspezifisch ausgesprochen. ===

Effect of combinations of drugs on all cause mortality in patients with ischaemic
heart disease: nested case-control analysis.

Institut
School of Community Health Sciences, University Park, Nottingham
Objective
To determine the effect of combinations of statins, aspirin, beta blockers, and angiotensin converting enzyme inhibitors in the secondary prevention of all cause mortality in patients with ischaemic heart disease. Open prospective cohort study with nested case-control analysis. 1.18 million patients registered with 89 general practices across 23 strategic health authority areas within the United Kingdom. Practices had longitudinal data for a minimum of eight years and were contributing to QRESEARCH, a new database.
Patients
All patients with a first diagnosis of ischaemic heart disease between January 1996 and December 2003. Cases were patients with ischaemic heart disease who died. Controls were patients with ischaemic heart disease who were matched for age, sex, and year of diagnosis and were alive at the time their matched case died.
Measures
Odds ratio with 95% confidence interval for risk of death in cases compared with controls. Exposure was current use of different combinations of statins, aspirin, beta blockers, and angiotensin converting enzyme inhibitors before death in cases, or the equivalent date in controls. 13,029 patients had a first diagnosis of ischaemic heart disease (incidence rate 338 per 100,000 person years). 2266 cases were matched to 9064 controls. Drug combinations associated with the greatest reduction in all cause mortality were statins, aspirin, and beta blockers (83% reduction, 95% confidence interval 77% to 88%); statins, aspirin, beta blockers, and angiotensin converting enzyme inhibitors (75% reduction, 65% to 82%); and statins, aspirin, and angiotensin converting enzyme inhibitors (71% reduction, 59% to 79%). Treatments associated with the smallest reduction in all cause mortality were beta blockers alone (19% reduction, 37% reduction to 4% increase), angiotensin converting enzyme inhibitors alone (20% reduction, 1% to 35%), and combined statins and angiotensin converting enzyme inhibitors (31% reduction, 57% reduction to 12% increase).
Conclusion
Combinations of statins, aspirins, and beta blockers improve survival in high risk patients with cardiovascular disease, although the addition of an angiotensin converting enzyme inhibitor conferred no additional benefit despite the analysis being adjusted for congestive cardiac failure. 9 Zusammenfassung

Empfehlung


Quelle Zeitschrift
PMID Nummer
Titel

Institut

Background

Conclusion

Quelle Zeitschrift
PMID Nummer
Titel

Institut

Background

Conclusion

Source: http://rmhc.de/pdfs/literaturservice2.pdf